Semax_Dosage, benefits & legal status

Guides for this compound

• How to Reconstitute a Peptide

  Mix peptide powder with bacteriostatic water, step by step.

• How to Read an Insulin Syringe

  Read the units, convert to millilitres, and draw the exact dose.

• mcg vs mg: The Peptide Dosing Mistake to Avoid

  Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.

• How to Read a Peptide COA

  What the purity number does and does not tell you, and how to spot an edited report.

• How to Vet a Peptide Vendor

  Independent COAs, HPLC purity, and the red flags that mean walk away.

Sources

• Semax research review, Alzheimer's Drug Discovery Foundation(2025)
  An independent assessment by neuroscientists at a research foundation, and the most useful thing in it is what the reviewer could not do. Semax is a real drug in Russia, used there for stroke, encephalopathy, Parkinson's, optic nerve atrophy and neurological deficits in newborns. The reviewer went looking for the evidence behind that and reports being unable to access the original human data, because the studies are published in Russian and reachable only as abstracts. What is accessible amounts to two pilot studies in healthy volunteers and two in stroke patients. The clearest of them gave 24 healthy subjects intranasal semax and found a change in resting brain imaging signal, which is a measurement rather than a benefit. On dementia and cognitive ageing the report's entry for clinical evidence is a single word: none. Two further things belong on a page for people considering this compound. Every dose documented here is intranasal drops, one to two drops of a 0.1% solution twice daily in healthy people, while semax is widely sold for injection. And the side effect profile is drawn from a review rather than from primary safety data, with nasal discoloration in about 10% of patients and raised blood glucose in about 7% of diabetics, with long-term effects unknown.
• FDA, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026(2026)
  FDA brought Semax before its Pharmacy Compounding Advisory Committee on 24 July 2026, to consider adding it to the 503A bulks list. The uses evaluated were cerebral ischemia, migraine and trigeminal neuralgia. None of those is the cognitive or nootropic use Semax is sold for in the West. They match its registered Russian indications instead, which tells you what evidence was actually submitted for review. Two things about the page itself. It sets out the agenda and links FDA's briefing document for each substance, but it does not record how the vote went, so it tells you what was assessed rather than what was decided. And the page notes that advisory committees give non-binding recommendations which FDA generally follows but is not legally bound to, so even the vote would not be the final word.
• FDA, bulk drug substances for compounding that may present significant safety risks(2026)
  FDA lists semax as the heptapeptide. It cites immunogenicity risk for certain routes from aggregation and peptide-related impurities, and says it has no or only limited safety information for the proposed routes, so it cannot know whether the drug would cause harm in people. As of the 22 April 2026 version of this page, the substance sits in the second table, headed bulk drug substances nominated but withdrawn, rather than in the live category 2 list. The nomination was withdrawn, which is not the same as being approved or cleared: FDA still publishes the safety language above, and no longer has a nomination in front of it to evaluate.

Last reviewed 14 August 2026

Beyond these, 398 records are indexed. Browse the records